Kiniksa Pharmaceuticals International (MEX:KNSAN) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KNSAN Kiniksa Pharmaceuticals International PLC MEX:KNSAN
50 GF Score
Price MXN754.37
GF Value MXN601.54
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Kiniksa Pharmaceuticals International's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

MEX:KNSAN vs INDV, AMRX, RGC: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's Margin of Safety % (DCF Dividends Based) falls into.


MEX:KNSAN
50GF Score
Kiniksa Pharmaceuticals International PLC MEX:KNSAN
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Kiniksa Pharmaceuticals International (MEX:KNSAN) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of MXN754.37 is trading 25.4% above its estimated GF Value™ of MXN601.54.

Key valuation signals for MEX:KNSAN:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: MXN601.54 vs. price of MXN754.37 (25.4% above fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the MEX:KNSAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Other Exchanges KNSA:USA
Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
50GF Score

Get the complete analysis for MEX:KNSAN

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN754.37
Price
MXN601.54
GF Value